Deep tech

Are you curious about new technologies, and how they can lead to long-term sustainable value?

We think creatively at the intersection of business and technology, inventing solutions to redefine what you do.

Explore deep tech
  • 5G and wireless connectivity
  • Advanced computing
  • AI and data analytics
  • Biotechnology
  • Digital transformation
  • Physical AI
  • Quantum technology
  • Sustainability

Industries

You need a partner with intimate knowledge of your industry and proven experience of delivering value from deep tech breakthroughs.

Discover more about the work we do in your sector and how we can create real commercial advantage for you.

Explore industries
  • Aerospace
  • Agritech
  • Consumer
  • Defence and security
  • Energy
  • Life sciences
  • Medical devices
  • Pharmaceuticals
  • Retail and logistics
  • Semiconductor
  • Smart infrastructure
  • Telecommunications

Insights

Take a look at the latest insights, ideas and perspectives from CC.

Explore a cross-section of up-to-date content on the deep tech trends shaping the future of business and society.

Read insights
  • Expert perspectives
  • Client stories
  • Latest publications
  • Newsroom
  • Events

Careers

Are you looking for an opportunity for your abilities to be recognised, and make a real difference?

Whether you are just starting out or you’re an experienced professional, we would love to hear from you.

Search vacancies
  • Early careers
  • Experienced professionals
  • Culture and benefits
  • Use of AI in recruitment
  • Our stories
  • Job alerts
  • Deep tech
  • Industries
  • Insights
  • Careers
  • About us
  • Contact
  • Global EN
    • 日本語
  • Deep tech
    • 5G and wireless connectivity
    • Advanced computing
    • AI and data analytics
    • Biotechnology
    • Digital transformation
    • Physical AI
    • Quantum technology
    • Sustainability
  • Industries
    • Aerospace and Satellite
    • Agritech
    • Consumer
    • Defence and security
    • Energy
    • Life sciences
    • Medical devices
    • Pharmaceuticals
    • Retail and logistics
    • Semiconductor
    • Smart infrastructure
    • Telecommunications
  • Insights
    • Expert perspectives
    • Client stories
    • Latest publications
    • Newsroom
    • Events
  • Careers
    • Search vacancies
    • Early careers
    • Experienced professionals
    • Life at CC
    • Our stories
    • Job alerts
  • About us
  • Contact
  • Global EN
    • 日本語
Design the therapy: Insights from our 2026 Drug Delivery Innovation Summit

Design the therapy: Insights from our 2026 Drug Delivery Innovation Summit

by Philip Canner, Charlie Dean and Adam Tozer | 29th September 2026 | Latest research, Life sciences, Medical Devices, Pharmaceuticals

Explore insights from our 2026 Drug Delivery Innovation Summit on drug delivery devices, connected care, patient experience and therapy design.

Moving agentic AI from demo to R&D acceleration

Moving agentic AI from demo to R&D acceleration

by Florian Gräf | 2nd June 2026 | Life sciences, Pharmaceuticals, Semiconductor

Collaboration with Microsoft on the Microsoft Discovery agentic platform for scientific R&D reveals that the real impact is acceleration not automation

Rethinking diagnostics in the fight against antimicrobial resistance

Rethinking diagnostics in the fight against antimicrobial resistance

by Ben Wicks and Alejandra Sanchez | 5th March 2026 | Life sciences, Pharmaceuticals

Alejandra Sanchez and Ben Wicks explore why primary care needs timely, pragmatic insight, not lab-grade certainty, to enable better antibiotic decisions and stewardship.

What does ‘fast enough’ mean in primary care antibiotic prescribing?

What does ‘fast enough’ mean in primary care antibiotic prescribing?

by Alejandra Sanchez | 9th October 2025 | Life sciences

Time-to-result is critical for any diagnostic in primary care. Antibiotic prescribing can only be improved if results come fast enough to guide decision making. But what does ‘fast enough’ look like?

Unlocking the potential of IP-free gene editing to gain commercial advantage

Unlocking the potential of IP-free gene editing to gain commercial advantage

by Dr Matthew Armean-Jones | 29th July 2025 | Life sciences, Pharmaceuticals

CC’s transdisciplinary development team has created a way to democratise gene editing. This IP-free gene editing method avoids the timescales and costs involved with commercially licensing current CRISPR/Cas9 editing techniques.

Engineering biology is driving the new bio-industrial revolution

Engineering biology is driving the new bio-industrial revolution

by mattjackson | 28th July 2025 | Agritech, Consumer Products, Defence and Security, Life sciences, Pharmaceuticals

Engineering biology, the fusion of biology and engineering principles, will be key to solving some of humanity’s most urgent challenges – from climate change and food security to healthcare and more

« Older Entries

Be unconstrained

Embrace innovation

Make a difference

Get in touch

Hear about the latest industry trends, technology challenges and innovation breakthroughs with our quarterly email updates

Sign me up
CC-logo-full-white-2024
  • Privacy Policy
  • Terms of use
  • Modern slavery statement
  • Legals and Regulatory

THE
DEEP TECH
POWER
HOUSE of
CAPGEMINI

All rights reserved by Cambridge Consultants © 2026

  • Follow
  • Follow
  • Follow
  • Follow
Manage Cookie Consent
To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Functional Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes. The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
  • Manage options
  • Manage services
  • Manage {vendor_count} vendors
  • Read more about these purposes
View preferences
  • {title}
  • {title}
  • {title}